Read More

European Stocks Are Left In Shambles From Russia-Ukraine War: It May Be Time To Buy These 2 High Yielders

As the SPDR Portfolio Europe ETF (ARCA: SPEU) is down roughly 32% year-to-date, it may be a prime moment to hunt for stocks that have become undervalued in the European stock market. The SPDR Portfolio Europe ETF seeks to track the performance of the STOXX Europe Total Market Index, which is the European equivalent to the S&P 500 Index here in the U.S.

AZN

Read More

AstraZeneca Announced Ultomiris Approved in Europe for the Treatment of Adults with Generalized Myasthenia Gravis

Ultomiris (ravulizumab) has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. This decision marks the first and only approval for a long-acting C5 complement inhibitor for

AZN

Read More

AstraZeneca Announced Lynparza Approved in China for Ovarian Cancer

AstraZeneca and MSD's Lynparza (olaparib) has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination deficiency (HRD)-positive statu

AZN